Abzena PLC Edison issues research update on Abzena (ABZA)
15 September 2016 - 12:58AM
RNS Non-Regulatory
TIDMABZA
Abzena PLC
14 September 2016
London, UK, 14 September 2016
Edison issues research update on Abzena (ABZA)
Abzena announced a strong business update including a twelfth
Abzena inside product entering Phase I clinical development and
positive momentum in trading. This continues to underpin the
rationale behind expanding the company to provide a broader range
of services. We now use an estimated H117 cash position, which
decreases the valuation slightly to GBP140m, offset slightly by the
twelfth Abzena inside product.
We have slightly decreased our valuation to GBP140m (vs GBP143m)
or 102p per share (vs 104p). This is primarily due to updating our
estimated H117 cash position of GBP9.6m (vs GBP13.7m). We have also
included the twelfth Abzena inside product entering Phase I
clinical development, which adds $1.7m to our rNPV. We assume
similar parameters to previous Abzena inside products in Phase I:
peak sales of $750m, 1% royalty, launch in 2023 and a 15%
probability of success. Abzena continues to demonstrate the
potential in its integrated service offering and we expect
potential uplifts to valuation as its Abzena inside products
progress towards commercialisation, most notably GS-5745 in gastric
cancer (Phase III).
Click here to view the full report
All reports published by Edison are available to download free
of charge from its website: www.edisoninvestmentresearch.com
About Edison: Edison is an international equity research firm
with a team of over 110 analysts, investment and roadshow
professionals and works with both large and smaller capitalised
companies, blue chip institutional investors, wealth managers,
private equity and corporate finance houses to support their
capital markets activity. Edison provides services to more than 420
retained corporate and investor clients from offices in London, New
York, Frankfurt, Sydney and Wellington. Edison is authorised and
regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide
investment advice. Edison's reports are not solicitations to buy or
sell any securities.
Contact details: Learn more at www.edisongroup.com and connect
with Edison on:
LinkedIn www.linkedin.com/company/edison-investment-research
--------- ----------------------------------------------------
Twitter www.twitter.com/Edison_Inv_Res
--------- ----------------------------------------------------
YouTube www.youtube.com/edisonitv
--------- ----------------------------------------------------
Google+ https://plus.google.com/105425025202328783163/posts
--------- ----------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABSGDCRUBBGLS
(END) Dow Jones Newswires
September 14, 2016 10:58 ET (14:58 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024